결핵 치료제 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Tuberculosis Therapeutics Market is poised to register a 4.1% CAGR during 2024-2032, driven by the increasing prevalence of latent tuberculosis (TB) cases. According to NCBI, approximately 25% of the world's population is currently infected with Mycobacterium tuberculosis in a latent form. With nearly one-quarter of the world's population estimated to be infected with latent TB, there is an urgent need for effective therapeutic solutions to prevent the progression to active TB. This is pushing the demand for innovative treatments designed to target and eradicate latent infections before they become active.

There is a growing emphasis on combination therapy to enhance treatment outcomes. Combination therapy is particularly significant for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, where single-drug therapies often fall short. Recent developments have led to new drug combinations that target multiple aspects of TB infection, reducing the likelihood of resistance and improving overall patient outcomes. These combination regimens shorten treatment duration, enhance drug effectiveness, and improve patient adherence.

The tuberculosis therapeutics industry is classified based on disease type, therapy, route of administration, dosage form, distribution channel, and region.

The latent tuberculosis segment will grow rapidly through 2032, as it is a stage where the bacteria are inactive and not causing symptoms but can reactivate later, which presents a significant challenge for public health. The rise in latent TB cases is driving the demand for new and improved treatment regimens that can effectively prevent the progression of the disease. Recent advancements in drug development have led to the introduction of novel therapeutic agents and combination therapies specifically targeting latent TB.

The parenteral administration segment will witness decent traction through 2032, owing to rapid drug absorption, immediate therapeutic effects, and precise control over dosage. The increasing focus on parenteral administration in TB therapeutics is driven by the need for more effective and reliable treatment options, especially for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases. Recent innovations in parenteral formulations and delivery systems have improved drug stability, enhanced patient convenience, and minimized side effects.

Europe tuberculosis therapeutics industry size will grow rapidly over 2024-2032, driven by increased funding for TB research, heightened awareness campaigns, and the implementation of advanced healthcare policies. Countries within the region are experiencing a growing demand for innovative TB therapies and improved diagnostic tools to combat the disease effectively. A robust healthcare infrastructure, which supports the widespread adoption of new therapeutic modalities and drug delivery systems, will augment the growth of the TB therapeutics market in Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of Tuberculosis
    • 3.2.1.2 Increasing investment for healthcare infrastructure
    • 3.2.1.3 Rise in research and development activities
    • 3.2.1.4 Growing awareness and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Vendor matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Active TB
• 5.3 Latent TB

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 First-line therapy
• 6.3 Second-line therapy

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other route of administration

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Tablets
• 8.3 Capsules
• 8.4 Injection
• 8.5 Other dosage forms

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aventis Pharmaceuticals Limited
• 11.2 Bayer Health Care
• 11.3 Eli Lilly And Company
• 11.4 Johnson and Johnson Services; Inc.
• 11.5 Lupin
• 11.6 Macleods Pharmaceuticals Ltd.
• 11.7 Mylan N.V.
• 11.8 Otsuka Pharmaceutical Co., Ltd.
• 11.9 Pfizer Inc.
• 11.10 Sanofi.